Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Accumulated Expenses (2019 - 2023)

Historic Accumulated Expenses for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $53.5 million.

  • ADC Therapeutics' Accumulated Expenses fell 1464.3% to $53.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $53.5 million, marking a year-over-year decrease of 1464.3%. This contributed to the annual value of $68.5 million for FY2022, which is 13553380.0% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Accumulated Expenses is $53.5 million, which was down 1464.3% from $53.4 million recorded in Q2 2023.
  • ADC Therapeutics' 5-year Accumulated Expenses high stood at $68.5 million for Q4 2022, and its period low was $15430.0 during Q4 2019.
  • Moreover, its 5-year median value for Accumulated Expenses was $40.0 million (2021), whereas its average is $36.3 million.
  • In the last 5 years, ADC Therapeutics' Accumulated Expenses skyrocketed by 17524131.58% in 2021 and then plummeted by 1464.3% in 2023.
  • ADC Therapeutics' Accumulated Expenses (Quarter) stood at $15430.0 in 2019, then soared by 46.68% to $22633.0 in 2020, then surged by 110993.1% to $25.1 million in 2021, then surged by 172.4% to $68.5 million in 2022, then decreased by 21.91% to $53.5 million in 2023.
  • Its Accumulated Expenses was $53.5 million in Q3 2023, compared to $53.4 million in Q2 2023 and $57.4 million in Q1 2023.